Equities analysts forecast that FibroGen Inc (NASDAQ:FGEN) will announce earnings per share of ($0.39) for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for FibroGen’s earnings. The highest EPS estimate is $0.03 and the lowest is ($0.82). FibroGen posted earnings per share of $0.23 in the same quarter last year, which suggests a negative year-over-year growth rate of 269.6%. The company is expected to announce its next earnings results on Wednesday, February 26th.

On average, analysts expect that FibroGen will report full-year earnings of ($0.16) per share for the current financial year, with EPS estimates ranging from ($0.57) to $0.28. For the next year, analysts expect that the business will report earnings of ($0.48) per share, with EPS estimates ranging from ($1.76) to $1.82. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for FibroGen.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.02. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The company had revenue of $33.17 million for the quarter, compared to the consensus estimate of $31.61 million. During the same period last year, the company earned ($0.50) earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year.

FGEN has been the topic of a number of recent research reports. ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a report on Friday, November 8th. BidaskClub upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Mizuho reiterated a “buy” rating and issued a $72.00 price objective on shares of FibroGen in a report on Monday, November 18th. Finally, Zacks Investment Research downgraded shares of FibroGen from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $58.33.

In related news, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $34.74, for a total transaction of $195,412.50. Following the transaction, the senior vice president now directly owns 145,253 shares in the company, valued at $5,046,089.22. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider K Peony Yu sold 3,419 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $40.92, for a total transaction of $139,905.48. Following the transaction, the insider now owns 175,240 shares in the company, valued at $7,170,820.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,495 shares of company stock worth $1,636,069. 8.96% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of FGEN. Farallon Capital Management LLC increased its holdings in FibroGen by 85.7% during the second quarter. Farallon Capital Management LLC now owns 1,700,000 shares of the biopharmaceutical company’s stock worth $76,806,000 after buying an additional 784,421 shares during the last quarter. Hillhouse Capital Advisors LTD. boosted its position in FibroGen by 36.0% during the second quarter. Hillhouse Capital Advisors LTD. now owns 2,724,519 shares of the biopharmaceutical company’s stock worth $123,094,000 after purchasing an additional 721,232 shares during the period. JPMorgan Chase & Co. boosted its position in FibroGen by 36.8% during the second quarter. JPMorgan Chase & Co. now owns 1,686,079 shares of the biopharmaceutical company’s stock worth $75,115,000 after purchasing an additional 453,519 shares during the period. Nuveen Asset Management LLC boosted its position in FibroGen by 3,168.1% during the second quarter. Nuveen Asset Management LLC now owns 418,312 shares of the biopharmaceutical company’s stock worth $18,899,000 after purchasing an additional 405,512 shares during the period. Finally, Westfield Capital Management Co. LP bought a new position in FibroGen during the second quarter worth $13,938,000. Institutional investors and hedge funds own 68.71% of the company’s stock.

Shares of NASDAQ FGEN traded down $0.95 during midday trading on Friday, reaching $46.69. The company’s stock had a trading volume of 494,059 shares, compared to its average volume of 657,633. The company has a current ratio of 9.01, a quick ratio of 8.95 and a debt-to-equity ratio of 0.07. FibroGen has a fifty-two week low of $32.33 and a fifty-two week high of $61.23. The stock has a market capitalization of $4.13 billion, a price-to-earnings ratio of -45.33 and a beta of 1.84. The stock has a 50 day simple moving average of $40.91 and a 200-day simple moving average of $41.84.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also: What is a good dividend yield?

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.